Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infliximab maintenance therapy for fistulizing Crohn's disease.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Sands BE, et al. Among authors: fedorak rn. N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815. N Engl J Med. 2004. PMID: 14985485 Free article. Clinical Trial.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Sandborn WJ, et al. Among authors: fedorak rn. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. N Engl J Med. 2013. PMID: 23964933 Free article. Clinical Trial.
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Feagan BG, et al. Among authors: fedorak rn. N Engl J Med. 2005 Jun 16;352(24):2499-507. doi: 10.1056/NEJMoa042982. N Engl J Med. 2005. PMID: 15958805 Free article. Clinical Trial.
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Targan SR, et al. Among authors: fedorak rn. Gastroenterology. 2007 May;132(5):1672-83. doi: 10.1053/j.gastro.2007.03.024. Epub 2007 Mar 21. Gastroenterology. 2007. PMID: 17484865 Clinical Trial.
Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.
Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, Bourdages R, Macintosh DG, Dallaire C, Cohen A, Fedorak RN, Paré P, Bitton A, Saibil F, Anderson F, Donner A, Wong CJ, Zou G, Vandervoort MK, Hopkins M, Greenberg GR. Feagan BG, et al. Among authors: fedorak rn. Gastroenterology. 2014 Mar;146(3):681-688.e1. doi: 10.1053/j.gastro.2013.11.024. Epub 2013 Nov 21. Gastroenterology. 2014. PMID: 24269926 Clinical Trial.
Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M; Onercept Study Group. Rutgeerts P, et al. Among authors: fedorak rn. Clin Gastroenterol Hepatol. 2006 Jul;4(7):888-93. doi: 10.1016/j.cgh.2006.04.022. Epub 2006 Jun 22. Clin Gastroenterol Hepatol. 2006. PMID: 16797249 Clinical Trial.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P; Ustekinumab Crohn's Disease Study Group. Sandborn WJ, et al. Among authors: fedorak rn. Gastroenterology. 2008 Oct;135(4):1130-41. doi: 10.1053/j.gastro.2008.07.014. Epub 2008 Jul 17. Gastroenterology. 2008. PMID: 18706417 Clinical Trial.
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Sandborn WJ, et al. Among authors: fedorak rn. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. doi: 10.1016/j.cgh.2010.04.021. Epub 2010 May 6. Clin Gastroenterol Hepatol. 2010. PMID: 20451663 Clinical Trial.
280 results